AllSci News
GelMEDIX Closes $13M Seed Round, Partners With Global Pharma on Hydrogel Stem Cell Therapies
GelMEDIX, Inc., a privately held biotechnology company based in Cambridge, Massachusetts, announced the completion of a $13 million seed financing round...
Sensorion pushes AAV gene therapy targeting connexin 26 mutations toward clinic for most common genetic deafness
Sensorion, a French clinical-stage biotechnology company, announced on March 23, 2026, that it is advancing SENS-601 (GJB2-GT), an AAV-based gene therapy...
Apogee Therapeutics' zumilokibart maintains atopic dermatitis responses with every-three-to-six-month dosing in Phase II trial
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotech based in San Francisco and Boston, reported 52-week maintenance data from the Phase II APEX...
FDA Grants Hemab Therapeutics Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia
Hemab Therapeutics, a late-stage clinical biotechnology company headquartered in Cambridge, Massachusetts, and Copenhagen, Denmark, announced that the U.S....
Earendil Labs Raises USD 787m to Advance AI-Driven Biologics Discovery and Development Pipeline
Earendil Labs, a Wilmington, Delaware-headquartered biotechnology company focused on AI-driven biologics discovery and development, has closed USD 787...
Atavistik Bio Raises USD 40 Million Series B Extension, Totaling USD 160 Million Round
Atavistik Bio Closes USD 40 Million Series B Extension, Bringing Total Round to USD 160 Million
Insilico Medicine and Lilly sign USD 2.75b multi-target AI drug discovery collaboration
Insilico Medicine's Pharma.AI platform is the centerpiece of a new multi-program drug discovery collaboration with Eli Lilly and Company (NYSE: LLY) that...
Oryon Cell Therapies Exits Stealth With USD 42m Series A for Parkinson's Cell Therapy
Oryon Cell Therapies, a clinical-stage company headquartered in Belmont, Massachusetts, has emerged from stealth with USD 42 million in total financing...
Compass Therapeutics Launches Phase 1 Trial of CTX-10726 PD-1×VEGF-A Bispecific in Advanced Cancers
Compass Therapeutics (NASDAQ: CMPX) has registered a Phase 1 CTX-10726 clinical trial (NCT07419841) that will mark the first time the tetravalent PD-1 ×...
Dong-A ST Advances CLDN18.2-Targeting ADC DA-3501 Into Phase I/IIa Trial for Gastric Pancreatic Cancer
South Korean pharmaceutical company Dong-A ST has registered a first-in-human Phase I/IIa clinical trial for DA-3501, a Claudin 18.2-targeting antibody-drug...
FDA approves Novo Nordisk's Awiqli, the first once-weekly basal insulin for type 2 diabetes
The US FDA has approved Awiqli (insulin icodec-abae) injection 700 units/mL, developed by Novo Nordisk, as an adjunct to diet and exercise to improve...
BridgeBio's ribitol therapy BBP-418 shows 31-second walk improvement over placebo in phase 3 LGMD2I/R9 trial
BridgeBio Pharma has presented interim results from FORTIFY, its Phase 3 trial of oral BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The...
FDA Resumes Review of Capricor's Deramiocel for Duchenne Muscular Dystrophy Cardiomyopathy
The US FDA has resumed review of a Biologics License Application (BLA) from Capricor Therapeutics for Deramiocel (CAP-1002), an allogeneic...
Jacobio receives USD 100m upfront from AstraZeneca for pan-KRAS inhibitor JAB-23E73 license deal
Jacobio Pharma confirmed receipt of a USD 100 million upfront payment from AstraZeneca under the license and collaboration agreement for JAB-23E73, a...
VeonGen Therapeutics' VG801 gene therapy shows early promise in ABCA4-associated Stargardt disease trial
VeonGen Therapeutics, a clinical-stage company based in Munich, Germany, announced preliminary data from its ongoing Phase I/II first-in-human trial of...
The AllSci Brief
Systematic R&D and deal news. Daily.